Treatment patterns and outcomes with HER2-directed therapy for the treatment of HER2-positive metastatic breast cancer.

被引：0
|
作者：
Luthra, Rakesh
Fisher, Maxine
Brammer, Melissa
Lalla, Deepa
机构：
[1] HealthCore Inc, Wilmington, DE USA
[2] Genentech Inc, San Francisco, CA 94080 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11063
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Treatment of HER2-positive breast cancer
    Figueroa-Magalhaes, Maria Cristina
    Jelovac, Danijela
    Connolly, Roisin M.
    Wolff, Antonio C.
    BREAST, 2014, 23 (02): : 128 - 136
  • [22] HER2-directed therapy in metastatic colorectal cancer
    Gourd, Katherine
    LANCET ONCOLOGY, 2022, 23 (08): : 988 - 988
  • [23] TRASTUZUMAB EMTANSINE FOR THE TREATMENT OF HER2-POSITIVE METASTATIC BREAST CANCER
    Haddley, K.
    DRUGS OF TODAY, 2013, 49 (11) : 701 - 715
  • [24] Treatment of HER2-positive metastatic breast cancer - advances and challenges
    Lin, N.
    CANCER RESEARCH, 2021, 81 (04)
  • [25] Use of Pertuzumab for the Treatment of HER2-Positive Metastatic Breast Cancer
    Leticia De Mattos-Arruda
    Javier Cortes
    Advances in Therapy, 2013, 30 : 645 - 658
  • [26] Use of Pertuzumab for the Treatment of HER2-Positive Metastatic Breast Cancer
    De Mattos-Arruda, Leticia
    Cortes, Javier
    ADVANCES IN THERAPY, 2013, 30 (07) : 645 - 658
  • [27] Personalized treatment approach for HER2-positive metastatic breast cancer
    Pandey, Prashant
    Chaudhary, Rishabh
    Tripathi, Devika
    Lavudi, Kousalya
    Dua, Kamal
    Weinfeld, Michael
    Lavasanifar, Afsaneh
    Rajinikanth, P. S.
    MEDICAL ONCOLOGY, 2024, 41 (11)
  • [28] Treatment Goals in the Management of HER2-Positive Metastatic Breast Cancer
    O'Regan, Ruth
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (09) : 3 - 6
  • [29] Advancing outcomes of metastatic HER2-positive breast cancer
    Chumsri, Saranya
    LANCET, 2023, 401 (10390): : 1746 - 1747
  • [30] Outcomes After Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed Therapy
    Tsai, Chiaojung Jillian
    Li, Jing
    Gonzalez-Angulo, Ana M.
    Allen, Pamela K.
    Woodward, Wendy A.
    Ueno, Naoto T.
    Lucci, Anthony
    Krishnamurthy, Savitri
    Gong, Yun
    Yang, Wei
    Cristofanilli, Massimo
    Valero, Vicente
    Buchholz, Thomas A.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2015, 38 (03): : 242 - 247
12345